111043-06-2

Basic information

• Product Name: 1-(3-BROMOPYRIDIN-4-YL)ETHANONE
• Synonyms: 1-(3-BROMOPYRIDIN-4-YL)ETHANONE;1-(3-broMo-4-pyridinyl)ethanone;4-Acetyl-3-broMopyridine;1-(2-BroMo-pyridin-4-yl)-ethanone;ETHANAONE, 1-(3-BROMO-4-PYRIDINYL)-;1-(3-Bromopyridin-4-yl)ethan-1-one
• CAS NO: 111043-06-2
• Molecular Formula: C₇H₆BrNO
• Molecular Weight: 200.03264
• Mol File: 111043-06-2.mol

Chemical Properties

• Boiling Point: 265.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.534±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 1.17±0.18(Predicted)
• CAS DataBase Reference: 1-(3-BROMOPYRIDIN-4-YL)ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-BROMOPYRIDIN-4-YL)ETHANONE(111043-06-2)
• EPA Substance Registry System: 1-(3-BROMOPYRIDIN-4-YL)ETHANONE(111043-06-2)

Safety Data

• Hazardous Substances Data: 111043-06-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(3-Bromopyridin-4-yl)ethanone is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to be readily incorporated into complex molecular structures. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Chemistry:
In the field of organic chemistry, 1-(3-Bromopyridin-4-yl)ethanone is utilized as a versatile reagent for the preparation of a wide range of organic compounds. Its reactivity enables chemists to explore various synthetic pathways and create novel molecules with specific properties.
Used in Chemical Research:
1-(3-Bromopyridin-4-yl)ethanone is employed as a research tool in chemical investigations, particularly in studies focused on the synthesis and properties of pyridine-based compounds. Its unique structure and reactivity make it an interesting subject for understanding reaction mechanisms and developing new synthetic methodologies.
Safety Considerations:
It is important to handle 1-(3-Bromopyridin-4-yl)ethanone with care due to its toxic nature. Proper safety measures should be taken to avoid skin, eye, and respiratory system irritation. Appropriate personal protective equipment (PPE) and handling procedures are essential to minimize exposure and ensure the safety of those working with 1-(3-Bromopyridin-4-yl)ethanone.

InChI:InChI=1S/C7H6BrNO/c1-5(10)6-2-3-9-4-7(6)8/h2-4H,1H3

Upstream product

• 35227-78-2 diethyl (ethoxymagnesio)malonate 
• 71541-33-8 3-Bromoisonicotinoyl chloride 
• 909532-61-2 3-bromo-N-methyl-N-(methyloxy)-4-pyridinecarboxamide 
• 75-16-1 methylmagnesium bromide 
• 1122-54-9 methyl (4-pyridyl) ketone 
• 78948-09-1 acetyl hypofluorite 
• 118289-17-1 2-bromopyridine-4-carboxaldehyde 
• 66572-56-3 2-bromoisonicotinic acid 
• 1220126-97-5 1-(2-bromopyridin-4-yl)ethan-1-ol 
• 656257-69-1 2-bromo-N-methyl-N-(methyloxy)-4-pyridinecarboxamide 
• 58530-53-3 2,4-dibromopyridine 
• 127-19-5 N,N-dimethyl acetamide 
• 917-64-6 methyl magnesium iodide 
• 149227-04-3 1-(3-bromopyridin-4-yl)ethan-1-ol 

Downstream Products

• 1187669-62-0 4-(3-ethyl-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 
• 1187669-61-9 4-(3-ethynyl-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 
• 1187669-64-2 3-(4-{2-[(3-methylphenyl)amino]-1,3-thiazol-4-yl}-3-pyridinyl)-1-propanol 
• 1187669-63-1 3-(4-{2-[(3-methylphenyl)amino]-1,3-thiazol-4-yl}-3-pyridinyl)-2-propyn-1-ol 
• 1055073-69-2 2-(2-bromopyridin-4-yl)-propan-2-ol 
• 1187669-38-0 4-(2-bromo-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 
• 1187669-43-7 4-(2-ethyl-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 
• 1187669-71-1 N,N-dimethyl-4-{2-[(3-methylphenyl)amino]-1,3-thiazol-4-yl}-pyridin-2-amine 
• 1187669-42-6 4-(2-ethynyl-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 
• 1187669-45-9 3-(4-{2-[(3-methylphenyl)amino]-1,3-thiazol-4-yl}-2-pyridinyl)-1-propanol 
• 1187669-44-8 3-(4-{2-[(3-methylphenyl)amino]-1,3-thiazol-4-yl}-2-pyridinyl)-2-propyn-1-ol 
• 1187669-69-7 N-(3-methylphenyl)-4-[2-morpholin-4-yl-pyridin-4-yl]-1,3-thiazol-2-amine 
• 1187669-70-0 N-(3-methylphenyl)-4-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1,3-thiazol-2-amine 
• 1366407-37-5 1-[2-(4-fluorophenyl)pyridin-4-yl]ethanone 

Relevant articles and documents

Aminopyridyloxypyrazole derivative and preparation method and application thereof

The invention relates to an aminopyridyloxypyrazole derivative and a preparation method and application thereof. The structure of the aminopyridyloxypyrazole derivative is shown as a formula (I). The invention provides a brand-new aminopyridyloxypyrazole derivative which has obvious effects of inhibiting TGF [beta] R1 (ALK5) kinase activity and treating cancer or fibrosis related diseases, and the preparation method of the derivative is simple and easy to operate.

FARNESOID X RECEPTOR AGONISTS AND USES THEREOF

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

FARNESOID X RECEPTOR AGONISTS AND USES THEREOF

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORgT

The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I) or pharmaceutically acceptable salts thereof. (Formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.